Prosecution Insights
Last updated: November 12, 2026
Application No. 18/559,333

METHODS AND COMPOSITIONS THEREOF FOR SITE-SPECIFIC LABELING OF HUMAN IgG BY PROXIMITY-BASED SORTASE-MEDIATED LIGATION

Final Rejection §102§103§112§DOUBLEPATENT
Filed
Nov 06, 2023
Priority
May 07, 2021 — provisional 63/185,843 +2 more
Examiner
PAK, YONG D
Art Unit
1652
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Alphathera LLC
OA Round
2 (Final)
75%
Grant Probability
Favorable
3-4
OA Rounds
89%
With Interview

Examiner Intelligence

Grants 75% — above average
75%
Career Allowance Rate
713 granted / 955 resolved
+14.7% vs TC avg
Moderate +14% lift
Without
With
+14.2%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
51 currently pending
Career history
1016
Total Applications
across all art units

Office Action

§102 §103 §112 §DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION This application is a 371 of PCT/US22/28134. The amendment filed on August 4, 2026 has been entered. Election/Restrictions Applicant elected without traverse of Group I with a species election of (1) sortase A with SEQ ID NO:24 having point mutations selected from T156S, D176E, and D170E as the sortase, (2) Protein G Htb1 domain as the antibody binding domain, and (3) SEQ ID NO:1 (LPXTG) as the sortase recognition motif in the reply filed on March 4, 2026. Claims 4 and 7-29 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species/invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on March 4, 2026. Status of Claims Claims 1, 3-4, 7-29 are pending. Claims 4 and 7-29 are withdrawn. Claims 1 and 3 are under examination. Response to Amendments/Arguments Nucleotide and/or Amino Acid Sequence Disclosures Applicant’s arguments, see page 8 of the Remarks, filed August 4, 2026, with respect to nucleotide and/or amino acid sequences have been fully considered and are persuasive. The specification has been amended to recite sequence identifier for the sequences. Therefore, the objection to the drawings and the specification have been withdrawn. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Applicant’s arguments, see Section 1 at page 8 of the Remarks, filed August 4, 2026, with respect to claim 3 have been fully considered and are persuasive. Claim 3 has been amended to recite the sequence identifier for the sortase. Therefore, the rejection of claim 3 under 35 U.S.C. 112(b) has been withdrawn. Applicant’s arguments, see Sections 2 and 3 at pages 8-9 of the Remarks, filed August 4, 2026, with respect to claims 6, 30, and 32 have been fully considered and are persuasive. Claims 6, 30, and 32 have been cancelled. Therefore, the rejections of claims 6, 30, and 32under 35 U.S.C. 112(b) have been withdrawn. Claim Rejections - 35 USC § 112(a) Applicant's arguments, see page 9-10 of the Remarks, filed August 4, 2026, with respect to claims 1-3, 5-6, and 30-32 have been fully considered and are persuasive. Claim 1 has been amended to recite that the fusion protein comprises sortase A having at least 80% sequence identity to SEQ ID NO:24 and Protein G subdomain (AbBD) has at least 80% sequence identity to SEQ ID NO:23. Applicant' s argument that the specification provides numerous examples to support the claimed genus has been found persuasive. Therefore, the rejection of claims 1-3, 5-6, and 30-32 under 35 U.S.C. 112(a) for lack of written description has been withdrawn. Applicant's arguments, see page 9-10 of the Remarks, filed August 4, 2026, with respect to claims 1-3, 5-6, and 30-32 have been fully considered and are persuasive. Claim 1 has been amended to recite that the fusion protein comprises sortase A having at least 80% sequence identity to SEQ ID NO:24 and Protein G subdomain (AbBD) has at least 80% sequence identity to SEQ ID NO:23. Applicant's argument that the specification provides guidance to make the claimed fusion protein without undue experimentation has been found persuasive. Therefore, the rejection of claims 1-3, 5-6, and 30-32 under 35 U.S.C. 112(a) for lack enablement has been withdrawn. Claim Rejections - 35 USC § 102 Applicant’s arguments, see page 11 of the Remarks, filed August 4, 2026, with respect to claims 1-2, 5-6, and 31 have been fully considered and are persuasive. Claim 1 has been amended to recite point mutations for the sortase A variant, which is not taught by Tsourkas (US 2018/0344871 - form PTO-1449 and US 11,123,440 – form PTO-892). Therefore, the rejection of claims 1-2, 5-6, and 31 under 35 U.S.C. 102(a)(1) or 102(a)(2) has been withdrawn. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1 and 3 is/are rejected under 35 U.S.C. 103 as being unpatentable over Tsourkas (US 2018/0344871 - form PTO-1449 or US 11,123,440 – form PTO-892. US 2018/0344871 is used for specific portions of Tsourkas) and Liu (US 2024/0077502 – form PTO-892) and evidenced by Dasgupta (Isopeptide ligation catalyzed by quintessential sortase A: mechanistic cues from cyclic and branched oligomers of indolicidin. J Biol Chem. 2011 Jul 8;286(27):23996-4006 – form PTO-1449) and Emidio (Sortase-mediated labeling: Expanding frontiers in site-specific protein functionalization opens new research avenues. Curr Opin Chem Biol. 2024 Jun;80:102443. – form PTO-892). Regarding claim 1, Tsourkas discloses a composition for producing an antibody conjugate comprising a fusion protein comprising (1) a sortase A having the LPXTG recognition motif and (2) an antibody binding domain (AbBD) that binds to an antibody (Figures 1 and 29, [0010], [0023], [0051], [0073]-[0074], [0112], and [0150]). Tsourkas discloses that the antibody binding domain (AbBD) is a variant of a Protein G subdomain having the amino acid sequence of SEQ ID NO:2, wherein the variant has an amino acid replacement at A24 ([0074]). The Protein G subdomain of SEQ ID NO:2 of Tsourkas has 100% sequence identity to SEQ ID NO:23 of the instant application (see the sequence alignment below). Therefore, the variant having a single point mutation has at least 80% sequence identity to SEQ ID NO:23 of the instant application. Tsourkas does not teach a sortase A having at least 80% sequence identity to SEQ ID NO:24, having a D112E (D170E full length) amino acid substitution. Liu discloses wildtype S. aureus sortase A having the amino acid sequence of SEQ ID NO:1, which comprises an amino acid sequence having 100% sequence identity to the sortase A of SEQ ID NO:24 of the instant application ([0061]). Liu discloses a variant of wildtype S. aureus sortase A, wherein the Sortase A variant has the amino acid sequence of SEQ ID NO:2, which has at least 80% sequence identity to the sortase A of the instant application (see the sequence alignment below). Regarding claim 2, Liu discloses evolved sortase A variants having a D170E amino acid substitution relative to the sortase A of SEQ ID NO:2, which corresponds to D112E of SEQ ID NO:24 of the instant application ([0091] and [0112]). Liu discloses that the evolved sortase A variants recognize a motif other than LPXTG and allows for a broader application of sortase A ([0003]). Liu discloses that the evolved sortase A variant recognizes LMVGG (abstract and [0004]). The property of having isopeptide ligation activity is inherent to the evolved sortase A variant of Liu. S. aureus sortase A recognizes LPXTG motif and has isopeptide ligation activity, see Dasgupta (abstract and page 23996). Evolved Sortase A variant also recognize LMVGG motif also have isopeptide ligation activity, as evidenced by Emidio (page 2 and Figure 1). MPEP 2112. II. states that “[t]here is no requirement that a person of ordinary skill in the art would have recognized the inherent disclosure at the relevant time, but only that the subject matter is in fact inherent in the prior art reference.”. Therefore, in combining the above references, it would have been obvious to one having ordinary skill in the art before the claimed invention was effectively filed to modify the sortase A comprised in the composition of Tsourkas by introducing the D112E amino acid mutation. One of ordinary skill in the art would have been motivated to do so in order to broaden the application of the Sortase A comprised in the fusion protein. One of ordinary skill in the art would have had a reasonable expectation of success since Tsourkas discloses a composition comprising a fusion protein comprising of sortase A and an antibody binding domain and Liu discloses a S. aureus sortase A variant having the D112E amino acid substitution. See MPEP 2143. Therefore, the above references render claims 1 and 3 prima facie obvious. The applied reference (US 11,123,440) has a common inventor and assignee with the instant application. Based upon the earlier effectively filed date of the reference, it constitutes prior art under 35 U.S.C. 102(a)(2). This rejection under 35 U.S.C. 103 might be overcome by: (1) a showing under 37 CFR 1.130(a) that the subject matter disclosed in the reference was obtained directly or indirectly from the inventor or a joint inventor of this application and is thus not prior art in accordance with 35 U.S.C.102(b)(2)(A); (2) a showing under 37 CFR 1.130(b) of a prior public disclosure under 35 U.S.C. 102(b)(2)(B); or (3) a statement pursuant to 35 U.S.C. 102(b)(2)(C) establishing that, not later than the effective filing date of the claimed invention, the subject matter disclosed and the claimed invention were either owned by the same person or subject to an obligation of assignment to the same person or subject to a joint research agreement. See generally MPEP § 717.02. Applicant's arguments filed August 4, 2026 have been fully considered but they are not persuasive. Applicant argues that the claims are not obvious over Tsourkas and Liu because (1) claim 1 has been amended to recite that the sortase A has at least 80% sequence identity to SEQ ID NO:24, has D112E amino acid substitution, and catalyzes an isopeptide ligation reaction and (2) Tsourkas and Liu do not disclose that sortase A having the function of catalyzing an isopeptide ligation reaction. This is not found persuasive. The property of having isopeptide ligation activity is inherent to the evolved sortase A variant of Liu. S. aureus sortase A recognizes LPXTG motif and has isopeptide ligation activity, see Dasgupta (abstract and page 23996). Evolved Sortase A variant also recognize LMVGG motif also have isopeptide ligation activity, as evidenced by Emidio (page 2 and Figure 1). MPEP 2112. II. states that “[t]here is no requirement that a person of ordinary skill in the art would have recognized the inherent disclosure at the relevant time, but only that the subject matter is in fact inherent in the prior art reference.”. Hence the rejection has been maintained. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1 and 3 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-18 of U.S. Patent No. 11,123,440 (reference patent) in view of Tsourkas (US 2018/0344871 – form PTO-1449) and Liu (US 2024/0077502 – form PTO-892) and evidenced by Dasgupta (Isopeptide ligation catalyzed by quintessential sortase A: mechanistic cues from cyclic and branched oligomers of indolicidin. J Biol Chem. 2011 Jul 8;286(27):23996-4006 – form PTO-1449) and Emidio (Sortase-mediated labeling: Expanding frontiers in site-specific protein functionalization opens new research avenues. Curr Opin Chem Biol. 2024 Jun;80:102443. – form PTO-892). Although the claims at issue are not identical, they are not patentably distinct from each other because the claims the instant application and the claims of the reference patent are directed to a fusion protein comprising a sortase A and an antibody binding domain. Regarding claim 1 of the instant application, claims 1 and 10 of the reference patent recite a composition for producing an antibody conjugate comprising a fusion protein comprising (1) a protein and (2) an antibody binding domain (AbBD), that binds to an antibody. Claim 1 of the reference patent recites that the antibody binding domain is Protein G variant. Claim 1 of the reference patent recites that Protein G subdomain has the amino acid sequence of SEQ ID NO:2, wherein the variant has an amino acid replacement at A24. The Protein G subdomain of SEQ ID NO:2 of the reference patent has 100% sequence identity to SEQ ID NO:23 of the instant application (see the sequence alignment below “Tsourkas”). Therefore, the variant having a single point mutation has at least 80% sequence identity to SEQ ID NO:23 of the instant application. The claims of the reference patent do not recite a fusion protein comprising sortase A or sortase A having at least 80% sequence identity to SEQ ID NO:24 and having a D170E amino acid substitution. Regarding claim 1, Tsourkas discloses a composition for producing an antibody conjugate comprising a fusion protein comprising (1) a sortase A having the LPXTG recognition motif and (2) an antibody binding domain (AbBD) that binds to an antibody (Figures 1 and 29, [0010], [0023], [0051], [0073]-[0074], [0112], and [0150]). Tsourkas discloses that the antibody binding domain (AbBD) is a variant of a Protein G subdomain having the amino acid sequence of SEQ ID NO:2, wherein the variant has an amino acid replacement at A24 ([0074]). The Protein G subdomain of SEQ ID NO:2 of Tsourkas has 100% sequence identity to SEQ ID NO:23 of the instant application (see the sequence alignment below). Therefore, the variant having a single point mutation has at least 80% sequence identity to SEQ ID NO:23 of the instant application. Tsourkas does not teach a sortase A having at least 80% sequence identity to SEQ ID NO:24, having a D112E (D170E full length) amino acid substitution. Liu discloses wildtype S. aureus sortase A having the amino acid sequence of SEQ ID NO:1, which comprises an amino acid sequence having 100% sequence identity to the sortase A of SEQ ID NO:24 of the instant application ([0061]). Liu discloses a variant of wildtype S. aureus sortase A, wherein the Sortase A variant has the amino acid sequence of SEQ ID NO:2, which has at least 80% sequence identity to the sortase A of the instant application (see the sequence alignment below). Regarding claim 2, Liu discloses evolved sortase A variants having a D170E amino acid substitution relative to the sortase A of SEQ ID NO:2, which corresponds to D112E of SEQ ID NO:24 of the instant application ([0091] and [0112]). Liu discloses that the evolved sortase A variants recognize a motif other than LPXTG and allows for a broader application of sortase A ([0003]). Liu discloses that the evolved sortase A variant recognizes LMVGG (abstract and [0004]). The property of having isopeptide ligation activity is inherent to the evolved sortase A variant of Liu. S. aureus sortase A recognizes LPXTG motif and has isopeptide ligation activity, see Dasgupta (abstract and page 23996). Evolved Sortase A variant also recognize LMVGG motif also have isopeptide ligation activity, as evidenced by Emidio (page 2 and Figure 1).MPEP 2112. II. states that “[t]here is no requirement that a person of ordinary skill in the art would have recognized the inherent disclosure at the relevant time, but only that the subject matter is in fact inherent in the prior art reference.”. Therefore, it would have been obvious to one having ordinary skill in the art before the claimed invention was effectively filed to modify the fusion protein of the claims of the reference patent by using sortase A as the protein and introducing the D170E amino acid mutation into S. aureus sortase A. One of ordinary skill in the art would have been motivated to do so in order to broaden the application of the Sortase A comprised in the fusion protein. One of ordinary skill in the art would have had a reasonable expectation of success since the claims of the reference patent recites a composition comprising a fusion protein comprising of protein and an antibody binding domain, Tsourkas discloses a composition comprising a fusion protein comprising of sortase A and an antibody binding domain and Liu discloses a S. aureus sortase A variant having the D170E amino acid substitution Therefore, the conflicting claims are not patentably distinct from each other. Applicant's arguments filed August 4, 2026 have been fully considered but they are not persuasive. Applicant argues that the claims are patentable over the reference patent because (1) claim 1 has been amended to recite that the sortase A has at least 80% sequence identity to SEQ ID NO:24, has D112E amino acid substitution, and catalyzes an isopeptide ligation reaction and (2) the claims of the reference patent, Tsourkas and Liu do not disclose that sortase A having the function of catalyzing an isopeptide ligation reaction. This is not found persuasive. The property of having isopeptide ligation activity is inherent to the evolved sortase A variant of Liu. S. aureus sortase A recognizes LPXTG motif and has isopeptide ligation activity, see Dasgupta (abstract and page 23996). Evolved Sortase A variant also recognize LMVGG motif also have isopeptide ligation activity, as evidenced by Emidio (page 2 and Figure 1). MPEP 2112. II. states that “[t]here is no requirement that a person of ordinary skill in the art would have recognized the inherent disclosure at the relevant time, but only that the subject matter is in fact inherent in the prior art reference.”. Hence the rejection has been maintained. Conclusion Claims 1-32 are pending. Claims 4 and 7-29 are withdrawn. Claims 1 and 3 are under examination. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to YONG D PAK whose telephone number is (571)272-0935. The examiner can normally be reached M-Th: 5:30 am - 3:30 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert Mondesi can be reached on 408-918-7584. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /YONG D PAK/Primary Examiner, Art Unit 1652 Sequence alignment between the Protein G subdomain of SEQ ID NO:23 of the instant application (“Qy”) and the Protein G subdomain of SEQ ID NO:2 of Tsourkas (“Db”) US-15-573-757-2 Sequence 2, US/15573757 Publication No. US20180344871A1 GENERAL INFORMATION APPLICANT: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA APPLICANT: TSOURKAS, Andrew APPLICANT: HUI, James Z. TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR MAKING ANTIBODY CONJUGATES FILE REFERENCE: P-78910-US CURRENT APPLICATION NUMBER: US/15/573,757 CURRENT FILING DATE: 2017-11-13 PRIOR APPLICATION NUMBER: 62/160,130 PRIOR FILING DATE: 2015-05-12 PRIOR APPLICATION NUMBER: PCT/US16/32221 PRIOR FILING DATE: 2016-05-12 NUMBER OF SEQ ID NOS: 16 SEQ ID NO 2 LENGTH: 56 TYPE: PRT ORGANISM: Staphylococcal aureus Query Match 100.0%; Score 290; Length 56; Best Local Similarity 100.0%; Matches 56; Conservative 0; Mismatches 0; Indels 0; Gaps 0; Qy 1 MTFKLIINGKTLKGEITIEAVDAAEAEKIFKQYANDYGIDGEWTYDDATKTFTVTE 56 |||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 1 MTFKLIINGKTLKGEITIEAVDAAEAEKIFKQYANDYGIDGEWTYDDATKTFTVTE 56 Sequence alignment between the Sortase A of SEQ ID NO:24 of the instant application (“Qy”) and the Sortase A of SEQ ID NO:1 of Liu (“Db”) US-18-271-650-1 Filing date in PALM: 2023-07-10 Sequence 1, US/18271650 Publication No. US20240077502A1 GENERAL INFORMATION APPLICANT: The Broad Institute, Inc. APPLICANT: President and Fellows of Harvard College APPLICANT: The Brigham and Women's Hospital, Inc. TITLE OF INVENTION: AMYLOID PROTEIN MODIFYING SORTASES AND USES THEREOF FILE REFERENCE: B1195.70120US01 CURRENT APPLICATION NUMBER: US/18/271,650 CURRENT FILING DATE: 2023-07-10 PRIOR APPLICATION NUMBER: PCT/US2022/011897 PRIOR FILING DATE: 2022-01-11 PRIOR APPLICATION NUMBER: US 63/136,186 PRIOR FILING DATE: 2021-01-11 NUMBER OF SEQ ID NOS: 105 SEQ ID NO 1 LENGTH: 206 TYPE: PRT ORGANISM: Staphylococcus aureus Query Match 99.4%; Score 768; Length 206; Best Local Similarity 100.0%; Matches 147; Conservative 0; Mismatches 0; Indels 0; Gaps 0; Qy 2 QAKPQIPKDKSKVAGYIEIPDADIKEPVYPGPATPEQLNRGVSFAEENESLDDQNISIAG 61 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 60 QAKPQIPKDKSKVAGYIEIPDADIKEPVYPGPATPEQLNRGVSFAEENESLDDQNISIAG 119 Qy 62 HTFIDRPNYQFTNLKAAKKGSMVYFKVGNETRKYKMTSIRDVKPTDVEVLDEQKGKDKQL 121 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| Db 120 HTFIDRPNYQFTNLKAAKKGSMVYFKVGNETRKYKMTSIRDVKPTDVEVLDEQKGKDKQL 179 Qy 122 TLITCDDYNEKTGVWEKRKIFVATEVK 148 ||||||||||||||||||||||||||| Db 180 TLITCDDYNEKTGVWEKRKIFVATEVK 206 Sequence alignment between the Sortase A of SEQ ID NO:24 of the instant application (“Qy”) and the Sortase A variant of SEQ ID NO:2 of Liu (“Db”) Title: US-18-559-333-24 Perfect score: 773 Sequence: 1 MQAKPQIPKDKSKVAGYIEI..........YNEKTGVWEKRKIFVATEVK 148 Scoring table: BLOSUM62 Gapop 10.0 , Gapext 0.5 Searched: 1 seqs, 206 residues Total number of hits satisfying chosen parameters: 1 Minimum DB seq length: 0 Maximum DB seq length: inf Post-processing: Minimum Match 0% Maximum Match 100% Listing first 50 summaries Database : US-18-271-650-2.fasta:* SUMMARIES % Result Query No. Score Match Length DB ID Description ---------------------------------------------------------------------------- 1 701 90.7 206 1 US-18-271-650-2 AMYLOID PROTEIN MO ALIGNMENTS RESULT 1 US-18-271-650-2 Query Match 90.7%; Score 701; DB 1; Length 206; Best Local Similarity 91.8%; Matches 135; Conservative 5; Mismatches 7; Indels 0; Gaps 0; Qy 2 QAKPQIPKDKSKVAGYIEIPDADIKEPVYPGPATPEQLNRGVSFAEENESLDDQNISIAG 61 |||||||||||||||||||||||||||||||||| |||:||||| |||||||||||||:| Db 60 QAKPQIPKDKSKVAGYIEIPDADIKEPVYPGPATREQLDRGVSFVEENESLDDQNISISG 119 Qy 62 HTFIDRPNYQFTNLKAAKKGSMVYFKVGNETRKYKMTSIRDVKPTDVEVLDEQKGKDKQL 121 || ||||||||||| |||||||||||||||||||||||||:|||| |||||||||||||| Db 120 HTAIDRPNYQFTNLGAAKKGSMVYFKVGNETRKYKMTSIRNVKPTAVEVLDEQKGKDKQL 179 Qy 122 TLITCDDYNEKTGVWEKRKIFVATEVK 148 ||:|||||| :||||| |||||||||| Db 180 TLVTCDDYNVETGVWETRKIFVATEVK 206
Read full office action

Prosecution Timeline

Nov 06, 2023
Application Filed
Mar 04, 2026
Response after Non-Final Action
May 04, 2026
Non-Final Rejection mailed — §102, §103, §112
Aug 04, 2026
Response Filed
Oct 08, 2026
Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12781198
GENETICALLY MODIFIED METHYLOBACILLUS BACTERIA HAVING IMPROVING PROPERTIES
3y 7m to grant Granted Nov 03, 2026
Patent 12781212
MODIFIED L-ASPARAGINASE
3y 1m to grant Granted Nov 03, 2026
Patent 12781199
MICROORGANISM WITH IMPROVED PROTEIN PRODUCTIVITY AND USE THEREOF
2y 8m to grant Granted Nov 03, 2026
Patent 12767936
COMPOSITIONS AND METHODS FOR 2,5-FURAN DICARBOXYLIC ACID PRODUCTION
4y 1m to grant Granted Oct 20, 2026
Patent 12760293
HIGH EFFICIENCY OXALATE-DEGRADING ENZYMES FOR DEGRADATION OF INSOLUBLE AND SOLUBLE OXALATE
4y 6m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
75%
Grant Probability
89%
With Interview (+14.2%)
Moderate
PTA Risk
Based on 955 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month